|Bid||0.14 x 0|
|Ask||0.15 x 0|
|Day's Range||0.1500 - 0.1500|
|52 Week Range||0.1000 - 0.3300|
|Beta (3Y Monthly)||-2.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 27, 2018 - Dec 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three and nine months ended September 30, 2018, which are also available on SEDAR (www.sedar.com). MedX launched the Company’s ground-breaking DermSecureTM telemedicine platform during the third quarter. “DermSecureTM makes MedX’s rapid skin cancer assessment solution commercially scalable on a global basis,” commented Scott Spearn, CEO of MedX.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies. The consortium will integrate DermSecureTM with their existing platforms, which includes a suite of software applications used by a large majority of general practitioners in the Netherlands, and will build awareness campaigns through established healthcare initiatives and programs. “The Dutch team is impressed with SIAscopy’s unique scanning technology, and the ability to seamlessly integrate our DermSecureTM platform into their suite of medical software applications that are used by more than 4,500 physicians in the Netherlands makes it a natural fit,” noted Scott Spearn, MedX’s President and CEO.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an additional Closing of 1,137,500 Units on November 22, 2018, to raise $182,000 from accredited investors pursuant to a Private Placement Offering originally announced on October 11, 2018. Following this Closing, MedX has 135,053,901 common shares issued and outstanding. The Company also announces that it is initiating a new, non-brokered, Private Placement offering of Units to raise up to $2.5 million from accredited investors.
MedX Health Corp. (“MedX”) (MDX.V) announces that it is initiating the development of an Artificial Intelligence Engine with leading dermatologists and its technology partner, Blanc Labs, that will work in conjunction with its existing DermSecureTM screening platform. MedX has an opportunity to leverage Artificial Intelligence to create a unique assessment support tool allowing Dermatologists to more accurately assess suspicious moles and lesions from remote locations. MedX’s advanced SIAscopy imaging technology lends itself to AI because of the specialized image capture above and below the skin’s surface.
MedX Health Corp. (“MedX”) (MDX.V) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin. “The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world.
This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange. MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, has been appointed as Chairman of the Board in place of Gary Van Nest who has retired from that position and remains as a director.
MedX Health Corp. (“MedX”) (MDX.V) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with Electronic Medical Record (EMR’s) systems.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three and six months ended June 30, 2018, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $405,707 for the three months ended June 30, 2018, a 71.3% increase over revenue of $236,892 for the three months ended June 30, 2017. Revenues from the Company’s SIAscopy technology were $210,951 for the quarter, a 181% increase over the 2017 three-month period.
MedX Health Corp. (“MedX”) (MDX.V) announced today that Dr. Trevor Champagne, Clinician in Quality and Innovation at Toronto’s Women's College Hospital, has joined its Medical Advisory Board. “We are very pleased to have Dr. Champagne join our Medical Advisory Board as he brings unique skill sets, including expertise in Artificial Intelligence, virtual care and teledermatology, that are ideal in assisting MedX to more efficiently and quickly reach larger global markets,” said Scott Spearn, President of MedX.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three months ended March 31, 2018, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $226,122 for the three months ended March 31, 2018, compared with revenue of $239,810 for the three months ended March 31, 2017. Revenues from SIAscopy of $39,236 were 18% higher than the 2017 three-month period, while sales from the Company's therapeutic laser line of $186,886 were lower than in the prior year.
MedX Health Corp. (“MedX”) (MDX.V) announces that Dr. Daniel Siegel, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined its Medical Advisory Board.
MedX Health Corp. (“MedX”) (MDX.V) announced that it has shipped an initial order in excess of $120,000 of its SIAscopy technology to Spain through its marketing partnership with OncoTech LLC. “Completing this large order early in the second quarter reinforces the growing interest in our technology as a pain-free non-invasive skin assessment tool,” noted Rob von der Porten, MedX's CEO. “OncoTech sees this as a first step in gaining awareness followed by further market penetration in Spain, including the application of MedX’s telemedicine platform in this large market.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the year ended December 31, 2017, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,093,239 for the year ended December 31, 2017, an increase of 34% from revenue of $817,055 for the year ended December 31, 2016. Sales from the Company's therapeutic laser line grew by $341,488 during 2017, while revenue from SIAscopy, the Company’s skin assessment technology, was $65,304 lower in 2017 versus 2016.
MedX Health Corp. announced today that Scott Spearn, an experienced medical device executive, joined the MedX team as President. Mr. Spearn has successfully built sales and distribution channels for medical devices across Canada, the United States and Latin America.
MedX Health Corp. . The Company announces that it has received notice from the TSX-V accepting an Investor Relations Agreement entered into with Mi3 Communications Financières Inc.
MedX Health Corp. announced today it has received regulatory clearance from the New Zealand Medicines and Medical Devices safety authority to sell its SIAscope medical device in New Zealand.
MedX Health Corp. announced today that it received a Corporate Citizenship Award from the Melanoma Network of Canada for MedX’s work in raising melanoma awareness.
MedX Health Corp. is pleased to announce that it received an initial order in excess of $100,000 for its pain-free, non-invasive skin assessment SIAscopy technology for use in Spain through its marketing partnership with OncoTech LLC.
MedX Health Corp. announces that it intends to raise up to a further $1,500,000 from accredited investors, by issuance of up to 12,500,000 Units, at $0.12 per Unit.
MedX Health Corp. . The Company announces that, effective December 15, 2017, it closed a non-brokered private placement. On Closing of the placement, the Company raised gross proceeds of $725,679 to its treasury by issuance of 6,047,329 Units, comprising 6,047,329 common shares ”) and 6,047,329 share purchase warrants at $0.12 per Unit.